Related Experiment Video
Updated: Jan 14, 2026

Assessment of the Metabolic Profile of Primary Leukemia Cells
Published on: November 21, 2018
Postsepsis bradycardia in children with leukemia
J D Tobias1, P M Bozeman, D C Stokes
1Department of Anesthesiology/Critical Care Medicine, St. Jude Children's Research Hospital, Memphis, TN 38101-0318.
Pediatric patients with hematologic malignancies experiencing sepsis recovery may develop postsepsis bradycardia. This condition, likely due to altered beta-adrenergic function or humoral factors, is clinically insignificant and requires no intervention.
Area of Science:
- Pediatric critical care medicine
- Hematology-oncology
- Infectious diseases
Background:
- Sinus bradycardia was observed in children with hematologic malignancies recovering from sepsis.
- The etiology of this postsepsis bradycardia syndrome was not well-defined.
Purpose of the Study:
- To define the clinical characteristics of postsepsis bradycardia in pediatric oncology patients.
- To investigate potential causes and predisposing factors for this condition.
Main Methods:
- Retrospective chart review of pediatric intensive care unit (ICU) admissions.
- Identified children with persistent bradycardia (heart rate <5th percentile for age for >1 hour) after sepsis.
- Analyzed patient demographics, diagnoses, blood cultures, and clinical course.
Main Results:
- Seven children with acute leukemia developed postsepsis bradycardia.
- Common pathogens included Streptococcus mitis, Escherichia coli, and Klebsiella pneumoniae.
- Bradycardia resolved spontaneously within 24-72 hours without specific treatment; echocardiograms and ECGs were normal.
Conclusions:
- Postsepsis bradycardia in this cohort may stem from altered beta-adrenergic receptor function or unique humoral factors.
- Acute leukemia and prior sepsis treatment might predispose patients to this syndrome.
- The bradycardia was clinically insignificant, obviating the need for invasive diagnostic or therapeutic measures.
More Related Videos
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013